The effect of pioglitazone on nitric oxide synthase in patients with type 2 diabetes mellitus.
The aim of this study was to evaluate the effect of pioglitazone on nitric oxide in patients with type 2 diabetes and coronary artery disease. Twenty-seven patients with coronary artery disease and diabetes mellitus who had received coronary stenting were eligible for the study. They were assigned to the no insulin resistance (NIR) group, the insulin resistance (IR) group, and the pioglitazone group (30 mg once a day). Endothelial nitric oxide synthase (eNOS), inducible nitric oxide synthase (iNOS), tumor necrosis factor alpha (TNF-alpha), interleukin-6, leptin, and adiponectin were measured. In the pioglitazone group, eNOS, iNOS, and leptin were significantly lower and adiponectin was significantly higher than those in the IR group. Stepwise multiple regression analyses showed that eNOS correlated with TNF-alpha and iNOS correlated with leptin and TNF-alpha. Leptin was the strongest predictor of iNOS. Treatment with pioglitazone significantly reduced eNOS and iNOS by improving adipocytokine levels.
Nishio
Kazuaki
K
Third Department of Internal Medicine, School of Medicine, Showa University, Tokyo, Japan. kazukun@jg7.so-net.jp
Shigemitsu
Meiei
M
Kodama
Yusuke
Y
Itoh
Seiji
S
Konno
Noburu
N
Satoh
Ryuji
R
Katagiri
Takashi
T
Kobayashi
Youichi
Y
D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000379:methods; D003324:Coronary Artery Disease / Q000150:complications / Q000201:enzymology / Q000628:therapy; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy / Q000201:enzymology*; D004797:Enzyme-Linked Immunosorbent Assay; D005500:Follow-Up Studies; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007333:Insulin Resistance; D008297:Male; D019001:Nitric Oxide Synthase / Q000097:blood / Q000187:drug effects*; D052247:Nitric Oxide Synthase Type II / Q000097:blood / Q000187:drug effects; D052250:Nitric Oxide Synthase Type III / Q000097:blood / Q000187:drug effects; D000077205:Pioglitazone; D045162:Thiazolidinediones / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; D052250:Nitric Oxide Synthase Type III; D000077205:Pioglitazone